AK106 / Asahi Kasei Therapeutics - LARVOL DELTA

AK106-001616, a potent and selective inhibitor of cytosolic phospholipase A2: in vivo efficacy for inflammation, neuropathic pain, and pulmonary fibrosis. (PubMed, J Pharmacol Exp Ther) - "However, naproxen and celecoxib did not reverse the decrease in the paw withdrawal threshold in the CCI model. Furthermore, AK106-001616 reduced the disease score of bleomycin-induced lung fibrosis in rats. Herein, we describe the preclinical pharmacology of AK106-001616. We believe that readers of The Journal of Pharmacology and Experimental Therapeutics will be interested in this manuscript because our data demonstrate that oral AK106-001616 may provide valuable effects for wide indications without attendant gastrointestinal and cardiovascular risks."

Journal • Preclinical